Search Results
Feb 13, 2026, 15:16 ET Dr. Eric Haeger Scholarship for Future Doctors Announces National Opportunity Supporting Undergraduate Students Pursuing Careers in Medicine
Future Doctors is open to undergraduate students enrolled in accredited colleges or universities who are on a medical career track, including pre-med, health sciences, or closely related disciplines.Applicants are required to submit a thoughtful and well-written essay responding to the following
More news about: Dr. Eric Haeger Scholarship
Feb 13, 2026, 14:41 ET EURÓPSKA KOMISIA SCHVÁLILA LIEK UPLIZNA® OD SPOLOČNOSTI AMGEN NA LIEČBU GENERALIZOVANEJ MYASTÉNIE GRAVIS
Turuspekova S, Lisnic V, Leone MA. Epidemiológia myasténie gravis. J Med Life. 2021;14(1):7-16. Nowak R, Benatar M, Ciafaloni E, a kol. Skúšanie fázy 3 inebilizumabu pri generalizovanej myasténii gravis. N Engl J Med. 2025;392(23):2309-2320.Európska agentúra pre lieky. Prvá liečba
More news about: Amgen
Feb 13, 2026, 14:28 ET Caracal Supports HIDA's Med Supply Chain Conference
Healthcare Solutions. "The Med Supply Chain Conference brings the industry together at a critical moment to tackle our biggest challenges, and we're excited to exchange ideas with fellow suppliers and explore the innovations shaping the future of health care."The Med Supply Chain Conference will
More news about: Caracal Products & Services
Feb 13, 2026, 11:47 ET ЕВРОПЕЙСКАЯ КОМИССИЯ ОДОБРИЛА ПРЕПАРАТ AMGEN UPLIZNA ® ДЛЯ ЛЕЧЕНИЯ ГЕНЕРАЛИЗОВАННОЙ МИАСТЕНИИ
Turuspekova S, Lisnic V, Leone MA. The epidemiology of myasthenia gravis. J Med Life. 2021;14(1):7-16. Nowak R, Benatar M, Ciafaloni E, et al. A phase 3 trial of inebilizumab in generalized myasthenia gravis. N Engl J Med. 2025;392(23):2309-2320.Европейское агентство по лекарственным
More news about: Amgen
Feb 13, 2026, 11:41 ET EVROPSKÁ KOMISE SCHVÁLILA PŘÍPRAVEK UPLIZNA® SPOLEČNOSTI AMGEN PRO GENERALIZOVANOU MYASTENII GRAVIS
Lisnic V, Leone MA. The epidemiology of myasthenia gravis. J Med Life. (2021) 14 / (1) 7-16 Nowak R, Benatar M, Ciafaloni E, et al. A phase 3 trial of inebilizumab in generalized myasthenia gravis. N Engl J Med. (2025) 392 / (23) 2309-2320Evropská agentura
More news about: Amgen
Feb 13, 2026, 09:34 ET KOMISJA EUROPEJSKA ZATWIERDZA LEK UPLIZNA® FIRMY AMGEN W LECZENIU UOGÓLNIONEJ MIASTENII
myasthenia gravis (Epidemiologia miastenii). J Med Life. 2021;14(1):7-16.Nowak R, Benatar M, Ciafaloni E, et al. A phase 3 trial of inebilizumab in generalized myasthenia gravis (Badanie fazy 3 inebilizumabu w uogólnionej miastenii). N Engl J Med. 2025;392(23):2309-2320.European Medicines
More news about: Amgen
Feb 13, 2026, 02:00 ET EYE PCR erhält CE-Zeichen für fixOflex Endocapsular Device und ermöglicht damit die europäische Markteinführung
https://doi.org/10.2147/OPTH.S358059.Konopińska J, Młynarczyk M, Dmuchowska DA, Obuchowska I. Posterior Capsule Opacification: Ein Überblick über experimentelle Studien. J Clin Med. 2021;10(13):2847.
More news about: EYE PCR
Feb 13, 2026, 02:00 ET EYE PCR Receives CE Mark for fixOflex Endocapsular Device, Enabling European Market Introduction
https://doi.org/10.2147/OPTH.S358059.Konopińska J, Młynarczyk M, Dmuchowska DA, Obuchowska I. Posterior Capsule Opacification: A Review of Experimental Studies. J Clin Med. 2021;10(13):2847.
More news about: EYE PCR
Feb 13, 2026, 02:00 ET EYE PCR recibe el marcado CE para dispositivo endocapsular fixOflex
https://doi.org/10.2147/OPTH.S358059.Konopińska J, Młynarczyk M, Dmuchowska DA, Obuchowska I. Opacificación de la cápsula posterior: una revisión de estudios experimentales. J Clin Med. 2021;10(13):2847.
More news about: EYE PCR
Feb 13, 2026, 02:00 ET EYE PCR reçoit le marquage CE pour le dispositif endocapsulaire fixOflex, ce qui permet son introduction sur le marché européen.
https://doi.org/10.2147/OPTH.S358059.Konopińska J, Młynarczyk M, Dmuchowska DA, Obuchowska I. Opacification de la capsule postérieure : Un examen des études expérimentales. J Clin Med. 2021;10(13):2847.
More news about: EYE PCR
Feb 12, 2026, 19:00 ET Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 (Novel HER2 ADC) for First Line Treatment of HER2-positive Breast Cancer
[2] Tan M， Yu D. Molecular mechanisms of erbB2-mediated breast cancer chemoresistance. Adv Exp Med Biol. 2007;608:119-129. doi:10.1007/978-0-387-74039-3_9.
More news about: Innovent Biologics
Feb 12, 2026, 15:30 ET LA COMMISSION EUROPEENNE APPROUVE UPLIZNA® D'AMGEN DANS LE CADRE DU TRAITEMENT DE LA MYASTHÉNIE GRAVE GÉNÉRALISÉE
Turuspekova S, Lisnic V, Leone MA. The epidemiology of myasthenia gravis. J Med Life. 2021;14(1):7-16. Nowak R, Benatar M, Ciafaloni E, et al. A phase 3 trial of inebilizumab in generalized myasthenia gravis. N Engl J Med. 2025;392(23):2309-2320.European Medicines Agency. First treatment
More news about: Amgen
Feb 12, 2026, 15:15 ET La Comisión Europea aprueba UPLIZNA® de Amgen para la miastenia gravis generalizada
Turuspekova S, Lisnic V, Leone MA. The epidemiology of myasthenia gravis. J Med Life. 2021;14(1):7-16. Nowak R, Benatar M, Ciafaloni E, et al. A phase 3 trial of inebilizumab in generalized myasthenia gravis. N Engl J Med. 2025;392(23):2309-2320.Agencia Europea de Medicamentos. Primer
More news about: Amgen
Feb 12, 2026, 12:02 ET West Hollywood Med Spa Cupid Lips Hosts Cupid Compendium Conference, Raising Over $60,000 for HUGS Charity
multimedia:https://www.prnewswire.com/news-releases/west-hollywood-med-spa-cupid-lips-hosts-cupid-compendium-conference-raising-over-60-000-for-hugs-charity-302686396.htmlSOURCE
More news about: CUPID LIPS®
Feb 12, 2026, 09:00 ET EUROPEAN COMMISSION APPROVES AMGEN'S UPLIZNA® FOR GENERALIZED MYASTHENIA GRAVIS
Turuspekova S, Lisnic V, Leone MA. The epidemiology of myasthenia gravis. J Med Life. 2021;14(1):7-16. Nowak R, Benatar M, Ciafaloni E, et al. A phase 3 trial of inebilizumab in generalized myasthenia gravis. N Engl J Med. 2025;392(23):2309-2320.European Medicines Agency. First treatment
More news about: Amgen
Feb 12, 2026, 08:01 ET New "Hypertension Bites" Campaign Urges Adults to Prioritize Blood Pressure Control
and national disease burden attributable to high systolic blood pressure in youth and young adults: 2021 Global Burden of Disease Study analysis. BMC Med. 2025 Feb 6;23(1):74. doi: 10.1186/s12916-025-03918-1. PMID: 39915840; PMCID: PMC11804021.ii Centers for Disease Control and Prevention
More news about: Hypertension Control Alliance
Feb 12, 2026, 07:30 ET Karyopharm Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress
9. Mirza MR, et al. N Engl J Med. 2023; 388:2145-2158. 10. Eskander RN, et al. N Eng J Med. 2023;388:2159-2170.
More news about: Karyopharm Therapeutics Inc.
Feb 11, 2026, 13:39 ET VentureMed Group nombra a Bruce Fiedler como director financiero
espero trabajar con el equipo para impulsar el crecimiento y generar un impacto significativo para pacientes y médicos".Acerca de Venture Med GroupAcerca de VentureMed Group y el sistema FLEX Vessel Prep™. VentureMed Group, Inc. es una empresa privada pionera de dispositivos médicos
More news about: VentureMed Group
Feb 11, 2026, 10:05 ET VentureMed-Gruppe ernennt Bruce Fiedler zum Finanzvorstand
freue mich darauf, mit dem Team zusammenzuarbeiten, um das Wachstum voranzutreiben und den Patienten und Ärzten zu helfen."Über die Venture Med GruppeÜber die VentureMed-Gruppe und das FLEX Vessel Prep™ System Die VentureMed-Gruppe, Inc. ist ein bahnbrechendes, in Privatbesitz befindliches
More news about: VentureMed Group
Feb 11, 2026, 10:05 ET VentureMed Group Appoints Bruce Fiedler as Chief Financial Officer
is compelling, and I look forward to working with the team to drive growth and meaningful impact for patients and physicians."About Venture Med GroupAbout VentureMed Group & FLEX Vessel Prep™ System VentureMed Group, Inc. is a pioneering privately held medical device company based
More news about: VentureMed Group
Feb 11, 2026, 10:05 ET VentureMed Group Appoints Bruce Fiedler as Chief Financial Officer
is compelling, and I look forward to working with the team to drive growth and meaningful impact for patients and physicians."About Venture Med GroupAbout VentureMed Group & FLEX Vessel Prep™ System VentureMed Group, Inc. is a pioneering privately held medical device company based
More news about: VentureMed Group
Feb 11, 2026, 10:05 ET Le groupe VentureMed nomme Bruce Fiedler directeur financier
avec l'équipe pour stimuler la croissance et avoir un impact significatif pour les patients et les médecins. »À propos du groupe Venture MedÀ propos de VentureMed Group & FLEX Vessel Prep™ System VentureMed Group, Inc. est une société privée pionnière dans le domaine des dispositifs
More news about: VentureMed Group
Feb 11, 2026, 09:42 ET Takebe Named to TIME100 Health List of Most Influential Leaders
animal-based results published in the journal Med, was later featured in the Canada-based science show The Nature of Things and led to Takebe and colleagues receiving
More news about: Cincinnati Children's Hospital Medical Center
Feb 11, 2026, 08:50 ET BoomRx Expands Testosterone Replacement Therapy (TRT) Beyond the Clinic
providers expand hormone-replacement services beyond traditional clinic-based models. The injection-free formulation supports telemedicine platforms, med spas, wellness clinics, and hybrid medical practices seeking to offer TRT without the operational burden of in-office administration. Testosterone
More news about: BoomRx
Feb 11, 2026, 08:00 ET Alaska Airlines and Hawaiian Airlines introduce spring menus featuring regional favorites and chef-led dining
the Signature Fruit & Cheese Platter.In addition to the Beecher's debut, Alaska's popular Evergreens menu expands this season with the new Med In The Clouds, a Mediterranean‑inspired, plant‑forward option. Following the strong guest response to a recent vegan and gluten‑free bowl, we're continuing
More news about: Alaska Airlines